Shi-Jiang Li, PhD, Receives 2017 Alzheimer Award

Honored for ground-breaking work published in the Journal of Alzheimer’s Disease

June 27, 2017 - Amsterdam, NL – The Journal of Alzheimer’s Disease (JAD) is pleased to announce that Shi-Jiang Li, PhD, Professor of Biophysics, Radiology, and Psychiatry and Behavioral Medicine at the Medical College of Wisconsin, has been chosen as the recipient of the 2017 Alzheimer Award. It has been presented by the journal in recognition of his outstanding work on the development of the CARE index, potentially a significant new tool in the battle against Alzheimer’s disease (AD) that can be used to characterize risks associated with AD stages and quantify disease severity on an individual subject basis. More...

June 27, 2017

Significant Impact Factor Gains for AI and Computer Sciences Journals

June 23, 2017 - Amsterdam, NL – IOS Press announces significant Impact Factor growth in its journals in artificial intelligence, computer & communications sciences and mathematics, according to the 2016 Journal Citation Reports® (JCR) released by Clarivate Analytics this month. More...

June 23, 2017

Brain Stimulation Protocol Reduces Spasticity in Spinal Cord Injury Patients

Patients show improvements that persist after treatment ends, reports new study in Restorative Neurology and Neuroscience

June 19, 2017 - Amsterdam, NL – Spasticity, uncontrolled muscle contractions, is a common disorder experienced by patients with spinal cord injuries (SCI). Previous studies have shown that excitatory repetitive transcranial magnetic stimulation (rTMS) can reduce spasticity. In a new study published in Restorative Neurology and Neuroscience, researchers found that a protocol of rTMS, excitatory intermittent theta burst stimulation (iTBS), was successful in reducing spasticity in patients with SCI and therefore may be a promising therapeutic tool. More...

June 19, 2017

Researchers Seek Biomarker to Assess Spinal Muscular Atrophy Treatment

New Study in the Journal of Neuromuscular Diseases Underscores the Importance of Confirming the Validity of Potential Biomarkers in a Large Animal Model

June 16, 2017 - Amsterdam, NL – Spinal muscular atrophy (SMA) is the leading genetic cause of death in infants, affecting 1 in 11,000 live births. As promising new therapies such as those directly targeting survivor motor neuron (SMN) are entering clinical trials for infants, children, and adults with SMA, researchers are searching for biomarkers in blood that can monitor their effectiveness. Investigators now report in the Journal of Neuromuscular Diseases that SMN levels in blood do not track SMN levels in motor neurons, and therefore are not an informative biomarker for SMN-modulating therapies that are delivered intrathecally. Beyond providing important information for SMA trial planning going forward, their results also highlight the importance of carefully validating specific biomarkers in a preclinical trial situation. More...

June 16, 2017